Simoens Steven, Decramer Marc
Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, K.U. Leuven, Onderwijs en Navorsing 2, Leuven, Belgium.
Expert Opin Pharmacother. 2007 Apr;8(5):633-48. doi: 10.1517/14656566.8.5.633.
Acute exacerbations of chronic obstructive pulmonary disease (COPD) impose a significant burden on society in terms of morbidity, mortality, reduced quality of life and healthcare expenditure. New generations of antibiotics are used to treat exacerbations, and other modes of delivery involving home support are being implemented. The optimal strategy to manage exacerbations on pharmacoeconomic grounds depends on issues such as diagnosis of an exacerbation and safety, effectiveness and costs of available alternatives. This review outlines the state of the art of pharmacoeconomic knowledge of the management of acute COPD exacerbations. It presents estimates of the level and distribution of costs associated with exacerbations and reports on the cost-effectiveness or cost-utility of antimicrobial therapy and other approaches to the management of exacerbations.
慢性阻塞性肺疾病（COPD）急性加重在发病率、死亡率、生活质量下降和医疗支出方面给社会带来了沉重负担。新一代抗生素被用于治疗急性加重，并且正在实施包括家庭支持在内的其他给药方式。基于药物经济学考虑，管理急性加重的最佳策略取决于诸如急性加重的诊断以及现有替代方案的安全性、有效性和成本等问题。本综述概述了急性COPD加重管理的药物经济学知识现状。它给出了与急性加重相关的成本水平和分布估计，并报告了抗菌治疗及其他急性加重管理方法的成本效益或成本效用。
